QuidelOrtho Corporation reported earnings results for the fourth quarter and full year ended December 28, 2025. For the fourth quarter, the company reported sales was USD 723.6 million compared to USD 707.8 million a year ago. Net loss was USD 130.7 million compared to USD 178.4 million a year ago. Basic loss per share from continuing operations was USD 1.92 compared to USD 2.65 a year ago. Diluted loss per share from continuing operations was USD 1.92 compared to USD 2.65 a year ago.
For the full year, sales was USD 2,730.2 million compared to USD 2,782.9 million a year ago. Sales was USD 2,730.2 million compared to USD 2,782.9 million a year ago. Sales was USD 2,730.2 million compared to USD 2,782.9 million a year ago. Sales was USD 2,730.2 million compared to USD 2,782.9 million a year ago. Net loss was USD 1,131.8 million compared to USD 2,052 million a year ago. Net loss was USD 1,131.8 million compared to USD 2,052 million a year ago. Net loss was USD 1,131.8 million compared to USD 2,052 million a year ago. Net loss was USD 1,131.8 million compared to USD 2,052 million a year ago. Basic loss per share from continuing operations was USD 16.69 compared to USD 30.54 a year ago. Basic loss per share from continuing operations was USD 16.69 compared to USD 30.54 a year ago. Basic loss per share from continuing operations was USD 16.69 compared to USD 30.54 a year ago. Basic loss per share from continuing operations was USD 16.69 compared to USD 30.54 a year ago. Diluted loss per share from continuing operations was USD 16.69 compared to USD 30.54 a year ago. Diluted loss per share from continuing operations was USD 16.69 compared to USD 30.54 a year ago. Diluted loss per share from continuing operations was USD 16.69 compared to USD 30.54 a year ago. Diluted loss per share from continuing operations was USD 16.69 compared to USD 30.54 a year ago.
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
